Key result
Inotropes in advanced HF lack mortality benefit but remain essential for bridging and palliative care.
Why the study?
The role of inotropes has expanded across multiple indications, yet there remains no consensus on the recommended inotrope for the failing heart.
Inotrope therapy remains a keystone for bridging to advanced therapies and palliative care in advanced heart failure, though it provides no mortality benefit and the choice of agent depends on the specific clinical scenario.
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to scenario-specific inotrope selection in advanced HF; extends AHA guidance via recent literature synthesis.
Neicheril et al. (2023) conducted a review in Heart failure. Inotropes was evaluated. Inotrope therapy in advanced heart failure provides no mortality benefit but remains a keystone for bridging to advanced therapies and palliative care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: